Achilles Therapeutics plc. launches an IPO.

IPO of Achilles Therapeutics plc. will take place on March 30, 2021. Achilles Therapeutics plc. is a biopharmaceutical company that works with immuno-oncological clinical stage. The company is developing precision T-cell therapy to treat several types of solid tumors.  The basis of the company's approach is the PELEUS bioinformatics platform, which is designed to identify each patient's own tumor-specific clonal neoantigens by comparing DNA sequencing information from healthy tissue and tumor tissue.  To address the limitations of current immuno-oncological approaches, the company has developed clonal neoantigen (cNeT) T-cells. The company creates a cNeT that is significantly enriched in T-cells designed to recognize and specifically target multiple clonal neoantigens in all tumor cells of a patient.

The listed IPO bookrunners are JP Morgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co.